PHASE 2 STUDY OF SEA-CD40 COMBINATION THERAPIES IN ADVANCED MALIGNANCIES (SGNS40002, TRIAL IN PROGRESS)JOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-071OA
THE ROLE OF COMBINATION IMMUNE CHECKPOINT INHIBITORS AS SALVAGE THERAPY FOR PD-1/PD-L1RESISTANT MERKEL CELL CARCINOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
ACTIVITY OF THE TUMOR-INTRINSIC NLRP3 INFLAMMASOME PATHWAY PREDICTS FOR RESPONSE TO CHECKPOINT INHIBITOR IMMUNOTHERAPY IN MELANOMA PATIENTSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-071OA
INVESTIGATION OF WNT LIGAND SIGNALING REGULATORS AS A PREDICTOR OF ANTI-PD-1 RESPONSE IN METASTATIC MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-090PREAI
A PHASE I TRIAL OF INTRATUMORAL PVSRIPO IN PATIENTS WITH UNRESECTABLE TREATMENT REFRACTORY MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-090PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向